Stay updated on Pembrolizumab Trastuzumab Combo in HER2+ Gastric Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Trastuzumab Combo in HER2+ Gastric Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Trastuzumab Combo in HER2+ Gastric Cancer Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    Change Detected
    Summary
    A new revision label v3.5.0 was added and the previous v3.4.3 revision label was removed.
    Difference
    0.1%
    Check dated 2026-03-18T17:50:31.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    Footer revision label updated from v3.4.2 to v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-11T15:43:07.000Z thumbnail image
  5. Check
    47 days ago
    Change Detected
    Summary
    Added 'Gastric cancer' as a topic label and included a 'Genetic and Rare Diseases Information Center' resource in the Resources section. This supplements patient information without modifying trial details.
    Difference
    0.2%
    Check dated 2026-02-18T07:30:47.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    The page now shows a new revision tag: Revision: v3.4.2. The older notice about lapse in government funding and operating status has been removed.
    Difference
    0.5%
    Check dated 2026-02-11T04:26:44.000Z thumbnail image
  7. Check
    61 days ago
    Change Detected
    Summary
    The update consists of an administrative notice about government funding and a revision tag from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2026-02-04T05:15:17.000Z thumbnail image
  8. Check
    68 days ago
    Change Detected
    Summary
    The update primarily adds UI elements and expands glossary/metadata labels (Show glossary, IPD data planning terms, and related MeSH terms) across the page, with no changes to the core study details, eligibility criteria, or outcome measures. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    48%
    Check dated 2026-01-28T03:24:52.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Trastuzumab Combo in HER2+ Gastric Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Trastuzumab Combo in HER2+ Gastric Cancer Clinical Trial page.